Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones

Abstract The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European neuropsychopharmacology 2015-03, Vol.25 (3), p.365-376
Hauptverfasser: Rickli, Anna, Hoener, Marius C, Liechti, Matthias E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 376
container_issue 3
container_start_page 365
container_title European neuropsychopharmacology
container_volume 25
creator Rickli, Anna
Hoener, Marius C
Liechti, Matthias E
description Abstract The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using human embryonic kidney 293 cells that express the respective human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone, α-pyrrolidinovalerophenone, 3,4-methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylenedioxy-α-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace amine-associated receptor 1 binding compared with the non-β-keto-amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist properties and are likely associated with more MDMA-like effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability.
doi_str_mv 10.1016/j.euroneuro.2014.12.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1669832719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X14003599</els_id><sourcerecordid>1669832719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-e4eaa0a2160b786639062ca985a1583c8274de21250c89b10612907c3dad7973</originalsourceid><addsrcrecordid>eNqNUk1v1DAUtBCIbgt_AXzkkuCPJI45IFVVKUhFINEDN-ut85b1krWD7ay0v4M_jNMtPXDiYlv2zBvPm0fIa85qznj3dlfjHINfllow3tRc1IyLJ2TFeyUr1XfiKVkxLZpKK_X9jJyntGOMt1Lq5-RMtJ1oGGtW5Pfn4APsnUeaI_g0hZgxUvADjWhxyiFS58sV2OyCp1MMGzdiomFDfTjgSKd0tNuwPB-QpnmdMniL6R39ChGqLYzhB3rIOFDYT1vM92LpXmE6xnCAERcn1ELeOl9O6QV5toEx4cuH_YLcfbi-u_pY3X65-XR1eVvZVre5wgYBGAjesXUx3EnNOmFB9y3wtpe2F6oZUHDRMtvrNWcdF5opKwcYlFbygrw5lS2efs2Ystm7ZHEcwWOYk-Fdp3spFNcFqk5QG0NKETdmim4P8Wg4M0sgZmceAzFLIIYLUwIpzFcPIvN6j8Mj728CBXB5AmBxenAYTbIOSwcHVwLIZgjuP0Te_1PDjs47C-NPPGLahTn60kjDTSoE822Zi2UsePmBbLWWfwCnebpJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1669832719</pqid></control><display><type>article</type><title>Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rickli, Anna ; Hoener, Marius C ; Liechti, Matthias E</creator><creatorcontrib>Rickli, Anna ; Hoener, Marius C ; Liechti, Matthias E</creatorcontrib><description>Abstract The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using human embryonic kidney 293 cells that express the respective human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone, α-pyrrolidinovalerophenone, 3,4-methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylenedioxy-α-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace amine-associated receptor 1 binding compared with the non-β-keto-amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist properties and are likely associated with more MDMA-like effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2014.12.012</identifier><identifier>PMID: 25624004</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Amphetamine ; Amphetamine - pharmacology ; Biogenic Monoamines - metabolism ; Biogenic Monoamines - pharmacology ; Cathinone ; Central Nervous System Stimulants - pharmacology ; Dopamine ; Dose-Response Relationship, Drug ; Drug Interactions ; HEK293 Cells ; Humans ; Internal Medicine ; Membrane Transport Proteins - metabolism ; Novel psychoactive substances ; Protein Binding - drug effects ; Psychiatry ; Pyrrolidines - pharmacology ; Receptors, Neurotransmitter - metabolism ; Serotonin ; Transporter ; Tritium - pharmacokinetics</subject><ispartof>European neuropsychopharmacology, 2015-03, Vol.25 (3), p.365-376</ispartof><rights>Elsevier B.V. and ECNP</rights><rights>2015 Elsevier B.V. and ECNP</rights><rights>Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-e4eaa0a2160b786639062ca985a1583c8274de21250c89b10612907c3dad7973</citedby><cites>FETCH-LOGICAL-c595t-e4eaa0a2160b786639062ca985a1583c8274de21250c89b10612907c3dad7973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924977X14003599$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25624004$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rickli, Anna</creatorcontrib><creatorcontrib>Hoener, Marius C</creatorcontrib><creatorcontrib>Liechti, Matthias E</creatorcontrib><title>Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>Abstract The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using human embryonic kidney 293 cells that express the respective human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone, α-pyrrolidinovalerophenone, 3,4-methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylenedioxy-α-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace amine-associated receptor 1 binding compared with the non-β-keto-amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist properties and are likely associated with more MDMA-like effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability.</description><subject>Amphetamine</subject><subject>Amphetamine - pharmacology</subject><subject>Biogenic Monoamines - metabolism</subject><subject>Biogenic Monoamines - pharmacology</subject><subject>Cathinone</subject><subject>Central Nervous System Stimulants - pharmacology</subject><subject>Dopamine</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Membrane Transport Proteins - metabolism</subject><subject>Novel psychoactive substances</subject><subject>Protein Binding - drug effects</subject><subject>Psychiatry</subject><subject>Pyrrolidines - pharmacology</subject><subject>Receptors, Neurotransmitter - metabolism</subject><subject>Serotonin</subject><subject>Transporter</subject><subject>Tritium - pharmacokinetics</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUk1v1DAUtBCIbgt_AXzkkuCPJI45IFVVKUhFINEDN-ut85b1krWD7ay0v4M_jNMtPXDiYlv2zBvPm0fIa85qznj3dlfjHINfllow3tRc1IyLJ2TFeyUr1XfiKVkxLZpKK_X9jJyntGOMt1Lq5-RMtJ1oGGtW5Pfn4APsnUeaI_g0hZgxUvADjWhxyiFS58sV2OyCp1MMGzdiomFDfTjgSKd0tNuwPB-QpnmdMniL6R39ChGqLYzhB3rIOFDYT1vM92LpXmE6xnCAERcn1ELeOl9O6QV5toEx4cuH_YLcfbi-u_pY3X65-XR1eVvZVre5wgYBGAjesXUx3EnNOmFB9y3wtpe2F6oZUHDRMtvrNWcdF5opKwcYlFbygrw5lS2efs2Ystm7ZHEcwWOYk-Fdp3spFNcFqk5QG0NKETdmim4P8Wg4M0sgZmceAzFLIIYLUwIpzFcPIvN6j8Mj728CBXB5AmBxenAYTbIOSwcHVwLIZgjuP0Te_1PDjs47C-NPPGLahTn60kjDTSoE822Zi2UsePmBbLWWfwCnebpJ</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Rickli, Anna</creator><creator>Hoener, Marius C</creator><creator>Liechti, Matthias E</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones</title><author>Rickli, Anna ; Hoener, Marius C ; Liechti, Matthias E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-e4eaa0a2160b786639062ca985a1583c8274de21250c89b10612907c3dad7973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amphetamine</topic><topic>Amphetamine - pharmacology</topic><topic>Biogenic Monoamines - metabolism</topic><topic>Biogenic Monoamines - pharmacology</topic><topic>Cathinone</topic><topic>Central Nervous System Stimulants - pharmacology</topic><topic>Dopamine</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Membrane Transport Proteins - metabolism</topic><topic>Novel psychoactive substances</topic><topic>Protein Binding - drug effects</topic><topic>Psychiatry</topic><topic>Pyrrolidines - pharmacology</topic><topic>Receptors, Neurotransmitter - metabolism</topic><topic>Serotonin</topic><topic>Transporter</topic><topic>Tritium - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rickli, Anna</creatorcontrib><creatorcontrib>Hoener, Marius C</creatorcontrib><creatorcontrib>Liechti, Matthias E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rickli, Anna</au><au>Hoener, Marius C</au><au>Liechti, Matthias E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>25</volume><issue>3</issue><spage>365</spage><epage>376</epage><pages>365-376</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>Abstract The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using human embryonic kidney 293 cells that express the respective human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone, α-pyrrolidinovalerophenone, 3,4-methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylenedioxy-α-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace amine-associated receptor 1 binding compared with the non-β-keto-amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist properties and are likely associated with more MDMA-like effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>25624004</pmid><doi>10.1016/j.euroneuro.2014.12.012</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0924-977X
ispartof European neuropsychopharmacology, 2015-03, Vol.25 (3), p.365-376
issn 0924-977X
1873-7862
language eng
recordid cdi_proquest_miscellaneous_1669832719
source MEDLINE; Elsevier ScienceDirect Journals
subjects Amphetamine
Amphetamine - pharmacology
Biogenic Monoamines - metabolism
Biogenic Monoamines - pharmacology
Cathinone
Central Nervous System Stimulants - pharmacology
Dopamine
Dose-Response Relationship, Drug
Drug Interactions
HEK293 Cells
Humans
Internal Medicine
Membrane Transport Proteins - metabolism
Novel psychoactive substances
Protein Binding - drug effects
Psychiatry
Pyrrolidines - pharmacology
Receptors, Neurotransmitter - metabolism
Serotonin
Transporter
Tritium - pharmacokinetics
title Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A11%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monoamine%20transporter%20and%20receptor%20interaction%20profiles%20of%20novel%20psychoactive%20substances:%20Para-halogenated%20amphetamines%20and%20pyrovalerone%20cathinones&rft.jtitle=European%20neuropsychopharmacology&rft.au=Rickli,%20Anna&rft.date=2015-03-01&rft.volume=25&rft.issue=3&rft.spage=365&rft.epage=376&rft.pages=365-376&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2014.12.012&rft_dat=%3Cproquest_cross%3E1669832719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1669832719&rft_id=info:pmid/25624004&rft_els_id=S0924977X14003599&rfr_iscdi=true